GRANULES · NSE
Granules India Limited
₹875.5
+0.59% (+₹5.1)
Prev. close
₹870.4
Volume
12,00,729
Delivery %
54.0%
As of
18 Sept 2026
Price history
Ajit Mishra · Religare Broking · 11 Sept 2026
“Bullish on Granules India, recommending a buy with a target price of ₹970 and a stop loss of ₹863. The stock shows an upside breakout from a flag pattern with rising volumes, maintaining higher highs and lows, and trading above all key moving averages, indicating sustained uptrend and further near-term upside potential.”
Entry ≈ ₹890.05 (first trade after call)Target ₹970 (+9.0%)Stop ₹863 (-3.0%)R:R ~3.0:1Stopped out · 16 Sept 2026
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Bullish on Granules India, recommending a buy with a target price of ₹970 and a stop loss of ₹863. The stock shows an up…” | Ajit MishraReligare Broking | Granules India Ltd | PENDING | ||||
“Bullish on Granules India, recommending a buy with a target price of ₹970 and a stop loss of ₹863. The stock shows an upside breakout from a flag pattern with rising volumes, maintaining higher highs and lows, and trading above all key moving averages, indicating sustained uptrend and further near-term upside potential.” This call hasn't reached its evaluation window yet — the verdict will appear here once it's graded. | |||||||
| “Bullish on Granules India, recommending a buy with a stop-loss at ₹840 and a target of ₹960. The stock shows a strong bu…” | Vaishali PatelJainam | Granules India | PENDING | ||||
Fundamentals
About Granules India Limited
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally. It offers paracetamol, metformin, guaifenesin, ibuprofen, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Krishna Prasad Chigurupati B.Sc.
Headquarters
Hyderabad
Employees
4,306
Website
granulesindia.comExchange
View on NSE ↗Key stats
Market cap
₹23,883.37 Cr
P/E ratio (TTM)
32.4
Dividend yield
0.20%
EPS (TTM)
₹26.98
Beta (1Y · daily vs NIFTY 50)
0.84
Beta (5Y · monthly vs NIFTY 50)
0.89
Shares float
16.76 Cr
EPS · quarter ended Jun 2026
₹7.12
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.3% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3,237.54 Cr | ₹3,764.92 Cr | ₹4,511.92 Cr | ₹4,506.37 Cr | ₹4,481.61 Cr | ₹5,365.64 Cr | |
| EBITDA | ₹882.11 Cr | ₹739.84 Cr | ₹927.60 Cr | ₹826.32 Cr | ₹946.34 Cr | ₹1,152.55 Cr |
| ₹549.00 Cr | ₹412.76 Cr | ₹516.60 Cr | ₹405.31 Cr | ₹501.52 Cr | ₹595.02 Cr | |
| Diluted EPS | ₹21.95 | ₹16.6 | ₹21 | ₹16.72 | ₹20.68 | ₹24.46 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3,713.00 Cr | ₹4,512.00 Cr | ₹4,903.00 Cr | ₹5,498.00 Cr | ₹6,221.00 Cr | ₹7,683.00 Cr | |
| — | — | ₹1,136.24 Cr | ₹1,315.06 Cr | ₹1,454.76 Cr | ₹1,512.04 Cr | |
| Stockholders' equity | ₹2,174.00 Cr | ₹2,587.00 Cr | ₹2,835.00 Cr | ₹3,225.00 Cr | ₹3,715.00 Cr | ₹5,085.00 Cr |
Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹432.00 Cr | ₹332.00 Cr | ₹739.00 Cr | ₹439.00 Cr | ₹867.00 Cr | ₹793.00 Cr | |
| Investing cash flow | ₹-277.14 Cr | ₹-380.11 Cr | ₹-191.36 Cr | ₹-360.16 Cr | ₹-691.29 Cr | ₹-773.21 Cr |
| ₹-299.31 Cr | ₹190.00 Cr | ₹-440.29 Cr | ₹7.66 Cr | ₹-92.51 Cr | ₹379.29 Cr | |
| Capital expenditure | ₹-271.00 Cr | ₹-398.00 Cr | ₹-411.00 Cr | ₹-381.00 Cr | ₹-572.00 Cr | ₹-558.00 Cr |
| End cash position | ₹41.84 Cr | ₹184.71 Cr | ₹291.56 Cr | ₹381.10 Cr | ₹466.11 Cr | ₹880.24 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Jun 22(3Q) | Sep 22 | Oct 22–Jun 23(4Q) | Sep 23–Mar 24(3Q) | Jun 24–Sep 24(2Q) | Dec 24 | Mar 25 | Jun 25–Dec 25(3Q) | Feb 26–Jun 26(3Q) |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 42.04% | 41.98% | 41.93% | 42.02% | 41.96% | 38.87% | 38.85% | 38.84% | 38.82% | 38.02% |
| Public | 57.96% | 58.02% | 58.07% | 57.98% | 58.04% | 61.13% | 61.15% | 61.16% | 61.18% | 61.98% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Granules India Limited | ₹20,705.91 Cr | ₹870.4 | 31.0 | 4.07 | 11.7% | 0.30 | +19.8% | +59.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 27
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
27 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Hyderabad Granules promoter sells 7% stake to raise 1.5k crore
The Times of India · 1 day ago
Granules India Promoter Chigurupati Sells 1.72 Cr Shares, Cuts Stake To 24.06%
Granules India promoter Dr. Krishna Prasad Chigurupati sold 1.72 crore shares, reducing his stake to 24.06%. The sale, valued at approximately Rs 1,160 crore, aims to fund the second tranche of the company’s preferential issue. This transaction supports Granules India's ongoing expansion plans.